Fibrinolytic Activity After Subarachnoid Haemorrhage and the Effect of Tranexamic Acid

Overview

Journal Acta Neurochir (Wien)

Specialty Neurosurgery

Date 1990 Jan 1

PMID 2205078

Citations 9

Authors

S A Tsementzis

W P Honan

S Nightingale

E R HITCHCOCK

C H Meyer

Affiliations

Soon will be listed here.

Abstract

Seventy-four patients with recent subarachnoid haemorrhage were randomly allocated to placebo or tranexamic acid treatment. Fibrinolytic activity in the blood and cerebrospinal fluid was assessed before treatment, one week later and two weeks later. The natural history of fibrinolysis following subarachnoid haemorrhage was obtained from analysis of the placebo group. Following subarachnoid haemorrhage, fibrin degradation products and plasminogen activity in the cerebrospinal fluid were elevated. Subsequently, fibrin degradation products in the cerebrospinal fluid fell progressively over the following 2 weeks. Changes in cerebrospinal fluid plasminogen activity correlated with those of blood plasminogen activity. Complications such as rebleeding, hydrocephalus or cerebral thrombosis could not be predicted from analysis of fibrinolytic activity. Tranexamic acid treatment resulted in a reduction in cerebrospinal fluid and blood plasminogen activity. The relevance of fibrinolysis in cerebrospinal fluid and blood to the management of subarachnoid haemorrhage is discussed.

Citing Articles

Antifibrinolytic therapy for aneurysmal subarachnoid haemorrhage.

Germans M, Dronkers W, Baharoglu M, Post R, Verbaan D, Rinkel G Cochrane Database Syst Rev. 2022; 11:CD001245.

PMID: 36350005 PMC: 9644641. DOI: 10.1002/14651858.CD001245.pub3.

Safety and Efficacy of Tranexamic Acid in Aneurysmal Subarachnoid Hemorrhage: A Meta-Analysis of Randomized Controlled Trials.

Ren J, Qian D, Wu J, Ni L, Qian W, Zhao G Front Neurol. 2022; 12:710495.

PMID: 35140671 PMC: 8818684. DOI: 10.3389/fneur.2021.710495.

Brain ischemia in patients with intracranial hemorrhage: pathophysiological reasoning for aggressive diagnostic management.

Naranjo D, Arkuszewski M, Rudzinski W, Melhem E, Krejza J Neuroradiol J. 2013; 26(6):610-28.

PMID: 24355179 PMC: 4202872. DOI: 10.1177/197140091302600603.

Antifibrinolytic therapy for aneurysmal subarachnoid haemorrhage.

Baharoglu M, Germans M, Rinkel G, Algra A, Vermeulen M, van Gijn J Cochrane Database Syst Rev. 2013; (8):CD001245.

PMID: 23990381 PMC: 8407182. DOI: 10.1002/14651858.CD001245.pub2.

Transient Obstructive Hydrocephalus due to Intraventricular Hemorrhage: A Case Report and Review of Literature.

Lusis E, Vellimana A, Ray W, Chicoine M, Jost S J Clin Neurol. 2013; 9(3):192-5.

PMID: 23894243 PMC: 3722471. DOI: 10.3988/jcn.2013.9.3.192.

References

Fodstad H . Antifibrinolytic treatment in subarachnoid haemorrhage: present state. Acta Neurochir (Wien). 1982; 63(1-4):233-44. DOI: 10.1007/BF01728877. View

Fodstad H, Forssell A, LILIEQUIST B, Schannong M . Antifibrinolysis with tranexamic acid in aneurysmal subarachnoid hemorrhage: a consecutive controlled clinical trial. Neurosurgery. 1981; 8(2):158-65. DOI: 10.1227/00006123-198102000-00004. View

Tsementzis S, HITCHCOCK E, Meyer C . Benefits and risks of antifibrinolytic therapy in the management of ruptured intracranial aneurysms. A double-blind placebo-controlled study. Acta Neurochir (Wien). 1990; 102(1-2):1-10. DOI: 10.1007/BF01402177. View

Tovi D . The use of antifibrinolytic drugs to prevent early recurrent aneurysmal subarachnoid haemorrhage. Acta Neurol Scand. 1973; 49(2):163-75. DOI: 10.1111/j.1600-0404.1973.tb01288.x. View

SHUCART W, Hussain S, Cooper P . Epsilon-aminocaproic acid and recurrent subarachnoid hemorrhage: a clinical trial. J Neurosurg. 1980; 53(1):28-31. DOI: 10.3171/jns.1980.53.1.0028. View

Gibbs J, OGorman P . Fibrinolysis in subarachnoid haemorrhage. Postgrad Med J. 1967; 43(506):779-84. PMC: 2466423. DOI: 10.1136/pgmj.43.506.779. View

Friberger P, Knos M, Gustavsson S, Aurell L, Claeson G . Methods for determination of plasmin, antiplasmin and plasminogen by means of substrate S-2251. Haemostasis. 1978; 7(2-3):138-45. DOI: 10.1159/000214252. View

Geronemus R, Herz D, Shulman K . Streptokinase clot lysis time in patients with ruptured intracranial aneurysms. J Neurosurg. 1974; 40(4):499-503. DOI: 10.3171/jns.1974.40.4.0499. View

NIBBELINK D, Torner J, Henderson W . Intracranial aneurysms and subarachnoid hemorrhage. A cooperative study. Antifibrinolytic therapy in recent onset subarachnoid hemorrhage. Stroke. 1975; 6(6):622-9. DOI: 10.1161/01.str.6.6.622. View

10.

Maurice-Williams R, Gordon Y, Sykes A . Monitoring fibrinolytic activity in the cerebrospinal fluid after aneurysmal subarachnoid haemorrhage: a guide to the risk of rebleeding?. J Neurol Neurosurg Psychiatry. 1980; 43(2):175-81. PMC: 490495. DOI: 10.1136/jnnp.43.2.175. View

11.

Sawaya R, Sonnino V, McLaurin R, Perrotta G . Monitoring of antifibrinolytic therapy following subarachnoid hemorrhage. The importance of CSF fibrin/fibrinogen degradation products. J Neurosurg. 1983; 58(5):699-707. DOI: 10.3171/jns.1983.58.5.0699. View

12.

MERSKEY C, Lalezari P, Johnson A . A rapid, simple, sensitive method for measuring fibrinolytic split products in human serum. Proc Soc Exp Biol Med. 1969; 131(3):871-5. DOI: 10.3181/00379727-131-33998. View

13.

Vermeulen M, van Vliet H, Lindsay K, Hijdra A, van Gijn J . Source of fibrin/fibrinogen degradation products in the CSF after subarachnoid hemorrhage. J Neurosurg. 1985; 63(4):573-7. DOI: 10.3171/jns.1985.63.4.0573. View

14.

Burchiel K, Hoffman J, Bakay R . Quantitative determination of plasma fibrinolytic activity in patients with ruptured intracranial aneurysms who are receiving epsilon-aminocaproic acid: relationship of possible complications of therapy to the degree of fibrinolytic inhibition. Neurosurgery. 1984; 14(1):57-63. DOI: 10.1227/00006123-198401000-00012. View

15.

Vermeulen M, Lindsay K, Murray G, Cheah F, Hijdra A, Muizelaar J . Antifibrinolytic treatment in subarachnoid hemorrhage. N Engl J Med. 1984; 311(7):432-7. DOI: 10.1056/NEJM198408163110703. View

16.

Ransohoff J, GOODGOLD A, Benjamin M . Preoperative management of patients with ruptured intracranial aneurysms. J Neurosurg. 1972; 36(5):525-30. DOI: 10.3171/jns.1972.36.5.0525. View

17.

Van Rossum J, Wintzen A, ENDTZ L, SCHOEN J, de Jonge H . Effect of tranexamic acid on rebleeding after subarachnoid hemorrhage: a double-blind controlled clinical trial. Ann Neurol. 1977; 2(3):238-42. DOI: 10.1002/ana.410020310. View

18.

Alvarez Garijo J, Vilches J, Aznar J . Preoperative treatment of ruptured intracranial aneurysms with tranexamic acid and monitoring of fibrinolytic activity. J Neurosurg. 1980; 52(4):453-5. DOI: 10.3171/jns.1980.52.4.0453. View

19.

Mullan S, Dawley J . Antifibrinolytic therapy for intracranial aneurysms. J Neurosurg. 1968; 28(1):21-3. DOI: 10.3171/jns.1968.28.1.0021. View

20.

Gibbs J, CORKILL A . Use of an anti-fibrinolytic agent (tranexamic acid) in the management of ruptured intracranial aneurysms. Postgrad Med J. 1971; 47(546):199-200. PMC: 2467076. DOI: 10.1136/pgmj.47.546.199. View